Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$545 Mln
Revenue (TTM)
$70 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.5
Industry P/E
--
EV/EBITDA
-0.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-4.9
Face value
--
Shares outstanding
62,781,400
CFO
$-1,939.58 Mln
EBITDA
$-2,521.30 Mln
Net Profit
$-2,469.96 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sage Therapeutic (SAGE)
| 59.9 | -5.1 | 14.2 | -19.6 | -36.8 | -28.3 | -18.6 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Sage Therapeutic (SAGE)
| -74.7 | -43.2 | -10.3 | -50.8 | 19.8 | -24.6 | -41.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA... receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. As of July 31, 2025, Sage Therapeutics, Inc. operates as a subsidiary of Saphire, Inc. Read more
President, CEO & Director
Mr. Barry E. Greene
President, CEO & Director
Mr. Barry E. Greene
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Sage Therapeutic (SAGE) is $8.68 (NASDAQ) as of 31-Jul-2025 09:30 EDT. Sage Therapeutic (SAGE) has given a return of -36.82% in the last 3 years.
Since, TTM earnings of Sage Therapeutic (SAGE) is negative, P/E ratio is not available.
The P/B ratio of Sage Therapeutic (SAGE) is 1.48 times as on 31-Jul-2025, a 62 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.82
|
0.71
|
|
2023
|
-2.40
|
1.63
|
|
2022
|
-4.51
|
1.81
|
|
2021
|
-5.56
|
1.45
|
|
2020
|
7.65
|
2.24
|
The 52-week high and low of Sage Therapeutic (SAGE) are Rs 11.44 and Rs 4.62 as of 04-Apr-2026.
Sage Therapeutic (SAGE) has a market capitalisation of $ 545 Mln as on 31-Jul-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Sage Therapeutic (SAGE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.